Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion type Assertion NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_head.
- NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion description "[First-line treatment in low-risk PV is phlebotomy to achieve a hematocrit target of 45% and low-dose aspirin, and first-line treatment in ET is observation alone in the absence of additional risk factors for arterial thrombosis (ie, JAK2 mutation and cardiovascular risk factors) or low-dose aspirin therapy, once or twice daily, in the presence of one or both of these risk factors, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_provenance.
- NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion evidence source_evidence_literature NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_provenance.
- NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion SIO_000772 26355403 NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_provenance.
- NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion wasDerivedFrom befree-2016 NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_provenance.
- NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion wasGeneratedBy ECO_0000203 NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_provenance.